Selective homocysteine-lowering gene transfer attenuates pressure overload-induced cardiomyopathy via reduced oxidative stress

Journal of Molecular Medicine

Volumn 93, Issue 6, 2015, Pages 609-618

  Muthuramu, Ilayaraja ^a   Singh, Neha ^a   Amin, Ruhul ^a   Nefyodova, Elena ^a   Debasse, Mirjam ^a   Van Horenbeeck, Isa ^a   Jacobs, Frank ^a   De Geest, Bart ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Cardiomyopathy; Gene transfer; Heart failure; Homocysteine; Transverse aortic constriction

Indexed keywords

3 NITROTYROSINE; ADENOVIRUS VECTOR; CYSTATHIONINE BETA SYNTHASE; CYSTEINE; FOLIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HOMOCYSTEINE; METHIONINE; N(G),N(G) DIMETHYLARGININE; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; AORTA CONSTRICTION; ARTICLE; CARDIOMYOPATHY; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG POTENCY; FEMALE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE OVERLOAD; HEART WEIGHT; HEMODYNAMIC PARAMETERS; HYPERHOMOCYSTEINEMIA; LUNG WEIGHT; MOUSE; NONHUMAN; OXIDATIVE STRESS; SHAM PROCEDURE; VIRAL GENE DELIVERY SYSTEM; ANIMAL; BLOOD; C57BL MOUSE; CARDIOMEGALY; CARDIOMYOPATHIES; COMPLICATION; GENE THERAPY; GENE TRANSFER; GENETICS; HEART MUSCLE; HEMODYNAMICS; PATHOLOGY;

ANIMALS; CARDIOMEGALY; CARDIOMYOPATHIES; CYSTATHIONINE BETA-SYNTHASE; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HEMODYNAMICS; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MICE, INBRED C57BL; MYOCARDIUM; OXIDATIVE STRESS;

EID: 84929192651     PISSN: 09462716     EISSN: 14321440     Source Type: Journal    
DOI: 10.1007/s00109-015-1281-3     Document Type: Article

References (49)

1. Sundstrom J, Sullivan L, Selhub J, Benjamin EJ, D’Agostino RB, Jacques PF, Rosenberg IH, Levy D, Wilson PW, Vasan RS (2004) Relations of plasma homocysteine to left ventricular structure and function: the Framingham Heart Study. Eur Heart J 25(6):523–530
2. Nasir K, Tsai M, Rosen BD, Fernandes V, Bluemke DA, Folsom AR, Lima JA (2007) Elevated homocysteine is associated with reduced regional left ventricular function: the Multi-Ethnic Study of Atherosclerosis. Circulation 115(2):180–187
3. Ruhui L, Jinfa J, Jiahong X, Wenlin M (2014) Influence of hyperhomocysteinemia on left ventricular diastolic function in Chinese patients with hypertension. Herz. doi:10.1007/s00059-014-4098-x
4. Washio T, Nomoto K, Watanabe I, Tani S, Nagao K, Hirayama A (2011) Relationship between plasma homocysteine levels and congestive heart failure in patients with acute myocardial infarction. Homocysteine and congestive heart failure. Int Heart J 52(4):224–228
5. Vasan RS, Beiser A, D’Agostino RB, Levy D, Selhub J, Jacques PF, Rosenberg IH, Wilson PW (2003) Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 289(10):1251–1257
6. May HT, Alharethi R, Anderson JL, Muhlestein JB, Reyna SP, Bair TL, Horne BD, Kfoury AG, Carlquist JF, Renlund DG (2007) Homocysteine levels are associated with increased risk of congestive heart failure in patients with and without coronary artery disease. Cardiology 107(3):178–184
7. Wang X, Cui L, Joseph J, Jiang B, Pimental D, Handy DE, Liao R, Loscalzo J (2012) Homocysteine induces cardiomyocyte dysfunction and apoptosis through p38 MAPK-mediated increase in oxidant stress. J Mol Cell Cardiol 52(3):753–760
8. Moshal KS, Tipparaju SM, Vacek TP, Kumar M, Singh M, Frank IE, Patibandla PK, Tyagi N, Rai J, Metreveli N et al (2008) Mitochondrial matrix metalloproteinase activation decreases myocyte contractility in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 295(2):H890–H897
9. Raaf L, Noll C, Cherifi Mel H, Samuel JL, Delcayre C, Delabar JM, Benazzoug Y, Janel N (2011) Myocardial fibrosis and TGFB expression in hyperhomocysteinemic rats. Mol Cell Biochem 347(1–2):63–70
10. Kundu S, Kumar M, Sen U, Mishra PK, Tyagi N, Metreveli N, Lominadze D, Rodriguez W, Tyagi SC (2009) Nitrotyrosinylation, remodeling and endothelial-myocyte uncoupling in iNOS, cystathionine beta synthase (CBS) knockouts and iNOS/CBS double knockout mice. J Cell Biochem 106(1):119–126
11. Muthuramu I, Jacobs F, Singh N, Gordts SC, De Geest B (2013) Selective homocysteine lowering gene transfer improves infarct healing, attenuates remodelling, and enhances diastolic function after myocardial infarction in mice. PLoS One 8(5), e63710. doi:10.1371/journal.pone.0063710
12. Buys ES, Raher MJ, Blake SL, Neilan TG, Graveline AR, Passeri JJ, Llano M, Perez-Sanz TM, Ichinose F, Janssens S et al (2007) Cardiomyocyte-restricted restoration of nitric oxide synthase 3 attenuates left ventricular remodeling after chronic pressure overload. Am J Physiol Heart Circ Physiol 293(1):H620–H627
13. Jacobs F, Van Craeyveld E, Muthuramu I, Gordts SC, Emmerechts J, Hoylaerts M, Herijgers P, De Geest B (2011) Correction of endothelial dysfunction after selective homocysteine lowering gene therapy reduces arterial thrombogenicity but has no effect on atherogenesis. J Mol Med 89(10):1051–1058
14. Jacobs F, Snoeys J, Feng Y, Van Craeyveld E, Lievens J, Armentano D, Cheng SH, De Geest B (2008) Direct comparison of hepatocyte-specific expression cassettes following adenoviral and nonviral hydrodynamic gene transfer. Gene Ther 15(8):594–603
15. Van Linthout S, Lusky M, Collen D, De Geest B (2002) Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector. Gene Ther 9(22):1520–1528
16. Gordts SC, Van Craeyveld E, Muthuramu I, Singh N, Jacobs F, De Geest B (2012) Lipid lowering and HDL raising gene transfer increase endothelial progenitor cells, enhance myocardial vascularity, and improve diastolic function. PLoS One 7(10), e46849. doi:10.1371/journal.pone.0046849
17. Van Craeyveld E, Jacobs F, Gordts SC, De Geest B (2012) Low-density lipoprotein receptor gene transfer in hypercholesterolemic mice improves cardiac function after myocardial infarction. Gene Ther 19(8):860–871
18. Van Craeyveld E, Gordts SC, Nefyodova E, Jacobs F, De Geest B (2011) Regression and stabilization of advanced murine atherosclerotic lesions: a comparison of LDL lowering and HDL raising gene transfer strategies. J Mol Med 89(6):555–567
19. Hu P, Zhang D, Swenson L, Chakrabarti G, Abel ED, Litwin SE (2003) Minimally invasive aortic banding in mice: effects of altered cardiomyocyte insulin signaling during pressure overload. Am J Physiol Heart Circ Physiol 285(3):H1261–H1269
20. Yasuno S, Kuwahara K, Kinoshita H, Yamada C, Nakagawa Y, Usami S, Kuwabara Y, Ueshima K, Harada M, Nishikimi T et al (2013) Angiotensin II type 1a receptor signalling directly contributes to the increased arrhythmogenicity in cardiac hypertrophy. Br J Pharmacol 170(7):1384–1395
21. Grossman W, Jones D, McLaurin LP (1975) Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest 56(1):56–64
22. Cohn JN (1993) Post-MI remodeling. Clin Cardiol 16(5 Suppl 2):II21–II24
23. Barrick CJ, Dong A, Waikel R, Corn D, Yang F, Threadgill DW, Smyth SS (2009) Parent-of-origin effects on cardiac response to pressure overload in mice. Am J Physiol Heart Circ Physiol 297(3):H1003–H1009
24. Heineke J, Molkentin JD (2006) Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7(8):589–600
25. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA (2002) Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105(1):85–92
26. Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF et al (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J 19(23):6341–6350
27. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH (1991) Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 114(5):345–352
28. Kupari M, Turto H, Lommi J (2005) Left ventricular hypertrophy in aortic valve stenosis: preventive or promotive of systolic dysfunction and heart failure? Eur Heart J 26(17):1790–1796
29. Herrmann W, Herrmann M, Joseph J, Tyagi SC (2007) Homocysteine, brain natriuretic peptide and chronic heart failure: a critical review. Clin Chem Lab Med 45(12):1633–1644
30. Gueant Rodriguez RM, Spada R, Pooya S, Jeannesson E, Moreno Garcia MA, Anello G, Bosco P, Elia M, Romano A, Alberto JM et al (2013) Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int J Cardiol 167(3):768–775
31. Sirker A, Zhang M, Murdoch C, Shah AM (2007) Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol 27(6):649–660
32. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ (1993) Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 14(11):1493–1498
33. Sorescu D, Griendling KK (2002) Reactive oxygen species, mitochondria, and NAD(P)H oxidases in the development and progression of heart failure. Congest Heart Fail 8(3):132–140
34. Handy DE, Zhang Y, Loscalzo J (2005) Homocysteine down-regulates cellular glutathione peroxidase (GPx1) by decreasing translation. J Biol Chem 280(16):15518–15525
35. Suematsu N, Ojaimi C, Kinugawa S, Wang Z, Xu X, Koller A, Recchia FA, Hintze TH (2007) Hyperhomocysteinemia alters cardiac substrate metabolism by impairing nitric oxide bioavailability through oxidative stress. Circulation 115(2):255–262
36. Kolling J, Scherer EB, da Cunha AA, da Cunha MJ, Wyse AT (2011) Homocysteine induces oxidative-nitrative stress in heart of rats: prevention by folic acid. Cardiovasc Toxicol 11(1):67–73
37. Dayal S, Arning E, Bottiglieri T, Boger RH, Sigmund CD, Faraci FM, Lentz SR (2004) Cerebral vascular dysfunction mediated by superoxide in hyperhomocysteinemic mice. Stroke; J Cereb Circ 35(8):1957–1962
38. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, Heydrick S, Stark R, Klings ES, Moldovan NI et al (2000) Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 106(4):483–491
39. Mishra PK, Tyagi N, Kundu S, Tyagi SC (2009) MicroRNAs are involved in homocysteine-induced cardiac remodeling. Cell Biochem Biophys 55(3):153–162
40. Ungvari Z, Csiszar A, Edwards JG, Kaminski PM, Wolin MS, Kaley G, Koller A (2003) Increased superoxide production in coronary arteries in hyperhomocysteinemia: role of tumor necrosis factor-alpha, NAD(P)H oxidase, and inducible nitric oxide synthase. Arterioscler Thromb Vasc Biol 23(3):418–424
41. Xie LH, Chen F, Karagueuzian HS, Weiss JN (2009) Oxidative-stress-induced afterdepolarizations and calmodulin kinase II signaling. Circ Res 104(1):79–86
42. Erickson JR, Joiner ML, Guan X, Kutschke W, Yang J, Oddis CV, Bartlett RK, Lowe JS, O’Donnell SE, Aykin-Burns N et al (2008) A dynamic pathway for calcium-independent activation of CaMKII by methionine oxidation. Cell 133(3):462–474
43. Cucoranu I, Clempus R, Dikalova A, Phelan PJ, Ariyan S, Dikalov S, Sorescu D (2005) NAD(P)H oxidase 4 mediates transforming growth factor-beta1-induced differentiation of cardiac fibroblasts into myofibroblasts. Circ Res 97(9):900–907
44. Zhao W, Zhao T, Chen Y, Ahokas RA, Sun Y (2008) Oxidative stress mediates cardiac fibrosis by enhancing transforming growth factor-beta1 in hypertensive rats. Mol Cell Biochem 317(1-2):43–50
45. Zhao QD, Viswanadhapalli S, Williams P, Shi Q, Tan C, Yi X, Bhandari B, Abboud HE (2015) NADPH oxidase 4 induces cardiac fibrosis and hypertrophy through activating Akt/mTOR and NFkappaB signaling pathways. Circulation 131(7):643–655
46. Dayal S, Rodionov RN, Arning E, Bottiglieri T, Kimoto M, Murry DJ, Cooke JP, Faraci FM, Lentz SR (2008) Tissue-specific downregulation of dimethylarginine dimethylaminohydrolase in hyperhomocysteinemia. Am J Physiol Heart Circ Physiol 295(2):H816–H825
47. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99(24):3092–3095
48. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP (2002) Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106(8):987–992
49. Stuhlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP (2001) Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 104(21):2569–2575